Accessibility Menu
Galera Therapeutics logo

Galera Therapeutics(OTC) GRTX

Current Price$17.50
Market Cap$20.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-99%
1 Year+271%
1 Month-5%
Galera Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 17.502026-07-24
Galera Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.49%USD 16.282026-07-17
1 month-4.89%USD 18.402026-06-24
3 month-12.5%USD 20.002026-04-24
Year to date+297.73%USD 4.402025-12-31
1 year+270.76%USD 4.722025-07-24
3 year-96.41%USD 488.002023-07-25
5 year-99.06%USD 1,862.002021-07-23
Since inception-99.27%USD 2,400.002019-11-07

Galera Therapeutics Financials at a Glance

Market Cap

$20.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$149.04M

EPS (TTM)

$396.88

P/E Ratio

0.04

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Price

$17.50

Volume

12

Open

$17.49

Previous Close

$17.50

Daily Range

$17.49 - $17.50

52-Week Range

$3.02 - $30.00

Estimated Earnings Date

Aug 12, 2026

GRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Galera Therapeutics

Galera develops medicines for people with aggressive breast cancers. Its main drug aims to help patients whose cancers do not respond to standard treatments. The company’s work focuses on improving outcomes for those with limited options.

Products and Services

  • Pan-NOS Inhibitor (tilarginine/L-NMMA): Experimental drug for rare and aggressive breast cancers; no revenue contribution (clinical stage).
  • Investigator-Sponsored Trials: Clinical studies funded by U.S. government agencies, targeting metaplastic and triple-negative breast cancer patients.
  • Intellectual Property Licensing: Exclusive rights to tilarginine for cancer use; supports future development, no current revenue.
  • Contingent Value Rights: Potential future payments from sold radiotherapy drug assets; no current revenue.

Growth and Expansion

  • Acquired Nova Pharmaceuticals in December 2024, shifting focus to breast cancer drugs.
  • Sold all radiotherapy drug assets to Biossil in October 2025 for $3.5 million upfront and possible future payments.
  • Launched new clinical trials for breast cancer drugs in 2025, partnering with Houston Methodist and NIH.
  • Reduced staff and expenses in 2025 to focus on core drug development.

What Makes Galera Stand Out

Galera operates with a lean team and outsources most research and manufacturing. It relies on government-funded trials to reduce costs. Exclusive patent rights support its focus on rare breast cancer treatments.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Operating expenses fell to $6 million in 2025, down 57.3% from 2024.
  • Net income was $149 million in 2025, due to a non-cash gain.
  • Cash and equivalents were $6.4 million at December 31, 2025, down 23.1% from 2024.

Bottom Line

Galera has shifted from radiotherapy drugs to rare breast cancer treatments. The company now relies on partnerships, lean operations, and exclusive patents to pursue its new direction.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

John Mel Sorensen, MD

Website

www.galeratx.com

Headquarters

Malvern, PA 19355, US

GRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-210.64%

Return on Capital

-92.23%

Return on Assets

2417.83%

Earnings Yield

25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.16M

Volume

12

Avg. Volume

537.096

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$5.73M

EBITDA

-$5.69M

Operating Cash Flow

-$1.63M

Capital Expenditure

$0.00

Free Cash Flow

-$1.63M

Cash & ST Invst.

$5.50M

Total Debt

$0.00

Galera Therapeutics Performance Analysis

Galera Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Galera Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Galera Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -459.43-26.4%
20232023-12-31USD -265.24-42.3%
20242024-12-31USD -69.40-73.8%
20252025-12-31USD 302.63N/A
Galera Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3062.5%
Q32025-09-30-29.4%
Q42025-12-3111163.8%
Q12026-03-31-101.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$20.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.76M

N/A

Employees

3

N/A

Net Income

-$1.61M

-0.9%

EBITDA

-$1.66M

+15.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.50M

-17.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

24.18%

N/A

Return on Invested Capital

-1.14%

N/A

Free Cash Flow

-$875.00K

+60.9%

Operating Cash Flow

-$875.00K

+60.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VCNXVaccinex, Inc.
$1.18+0.00%
MDGEFMedigene AG
$2.59+0.00%
HESGHealth Sciences Group, Inc.
$0.00+0.00%
NBCONeon Bloom, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About GRTX

What is the current price of Galera Therapeutics?

Galera Therapeutics is trading at $17.50 per share.

What is the 52-week range for Galera Therapeutics?

Over the past 52 weeks, Galera Therapeutics has traded between $3.02 and $30.00.

How much debt does Galera Therapeutics have?

As of the most recent reporting period, Galera Therapeutics reported total debt of $0.00.

How much cash does Galera Therapeutics have on hand?

Galera Therapeutics reported $5.50M in cash and cash equivalents in its most recent financial results.

What is Galera Therapeutics’s dividend yield?

Galera Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services